12:00 AM
 | 
Jan 09, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tesetaxel: Additional Phase IIb data

Additional data from an open-label, U.S. Phase IIb trial in 24 evaluable patients showed that oral tesetaxel every 21 days produced an ORR of 50%, including 1 complete response and 11 partial responses. Additionally, 6 of the 12 responders cleared >75% of their measurable disease. The DCR...

Read the full 213 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >